Sarepta Therapeutics,, Inc. (SRPT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SRPT SEC filings page.
Sarepta Therapeutics,, Inc. (SRPT) reported $2.0B in revenue over the twelve months to Jun 30, 2026, down 20.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue reached $2.2B , but heavy development spending reversed profitability, showing a business whose economics depend more on research investment than production cost.
2024’s accounting profit did not convert into operating cash: the company reported net income of$235M while operating cash flow was negative$206M . In FY2025, revenue increased while the net loss widened to$713M , yet operating cash flow remained near negative$205M , indicating that noncash items and working-capital movements materially separate reported earnings from cash use.
The margin structure is unusually top-heavy: FY2025 gross margin was
Liquidity remains substantial but less flexible than a year earlier: the current ratio fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sarepta Therapeutics,, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sarepta Therapeutics,, Inc. has an operating margin of -31.8%, meaning the company loses $32 on every $100 of revenue. This results in a profitability score of 22/100. This is down from 11.5% the prior year.
Sarepta Therapeutics,, Inc.'s revenue surged 15.6% year-over-year to $2.2B, reflecting rapid business expansion. This strong growth earns a score of 91/100.
Sarepta Therapeutics,, Inc. has a moderate D/E ratio of 0.73. This balance of debt and equity financing earns a leverage score of 54/100.
With a current ratio of 2.32, Sarepta Therapeutics,, Inc. holds $2.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 66/100.
Sarepta Therapeutics,, Inc.'s operations used $205.5M of cash, and capex of $102.0M added to the outflow, for a free cash flow shortfall of $307.5M. This results in a cash flow score of 8/100.
Sarepta Therapeutics,, Inc. posts a -62.5% return on equity (ROE), meaning it loses $63 for every $100 of shareholders' equity. This results in a returns score of 21/100. This is down from 15.4% the prior year.
Sarepta Therapeutics,, Inc. scores -1.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.8B) relative to total liabilities ($2.2B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sarepta Therapeutics,, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sarepta Therapeutics,, Inc. reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Sarepta Therapeutics,, Inc. reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Sarepta Therapeutics,, Inc. generated $401.3M in revenue in Q2 2026. This represents a decrease of 34.3% from the same quarter a year earlier. Against the prior quarter it is down 45.1%.
Sarepta Therapeutics,, Inc.'s EBITDA was $23.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 81.3% from the same quarter a year earlier. Against the prior quarter it is down 93.6%.
Sarepta Therapeutics,, Inc. reported -$4.9M in net income in Q2 2026. This represents a decrease of 102.5% from the same quarter a year earlier. Against the prior quarter it is down 101.5%.
Sarepta Therapeutics,, Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. This represents a decrease of 102.6% from the same quarter a year earlier. Against the prior quarter it is down 101.7%.
Cash & Balance Sheet
Sarepta Therapeutics,, Inc. generated $196.5M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 14.4% from the same quarter a year earlier. Against the prior quarter it is up 196.0%.
Sarepta Therapeutics,, Inc. held $571.1M in cash against $847.6M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Sarepta Therapeutics,, Inc.'s operating margin was 3.3% in Q2 2026, reflecting core business profitability. This is down 15.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 45.7 percentage points.
Sarepta Therapeutics,, Inc.'s net profit margin was -1.2% in Q2 2026, showing the share of revenue converted to profit. This is down 33.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 46.5 percentage points.
Sarepta Therapeutics,, Inc.'s ROE was -0.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 14.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.3 percentage points.
Not reported for Q2 2026.
Capital Allocation
Sarepta Therapeutics,, Inc. invested $91.3M in research and development in Q2 2026. This represents a decrease of 55.4% from the same quarter a year earlier. Against the prior quarter it is down 40.7%.
Sarepta Therapeutics,, Inc. invested $555K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 98.3% from the same quarter a year earlier. Against the prior quarter it is down 73.3%.
Not reported for Q2 2026.
SRPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $401.3M-34.3% | $730.8M-1.9% | $442.9M-32.7% | $399.4M-14.5% | $611.1M+68.4% | $744.9M+80.2% | $658.4M+65.9% | $467.2M+40.8% |
| Gross Profit | N/A | N/A | -$29.1M-105.8% | $219.3M-35.1% | $360.6M+14.1% | $474.0M+53.4% | $505.9M | $338.1M |
| R&D Expenses | $91.3M-55.4% | $154.0M-80.1% | N/A | $218.9M-2.5% | $204.4M+13.7% | $773.4M+286.0% | N/A | $224.5M+15.5% |
| SG&A Expenses | $107.6M-22.0% | $109.0M-18.5% | N/A | $91.9M-28.3% | $137.9M-0.6% | $133.6M+5.2% | N/A | $128.2M+6.0% |
| Operating Income | $13.3M-88.5% | $358.4M+219.3% | N/A | -$103.4M-565.8% | $115.6M+16587.4% | -$300.4M-960.6% | N/A | $22.2M+206.5% |
| EBITDA | $23.7M-81.3% | $369.0M+227.1% | N/A | -$84.9M-365.4% | $126.4M+1476.7% | -$290.4M-765.3% | N/A | $32.0M+422.8% |
| Interest Expense | -$21.5M-311.4% | -$21.7M-382.2% | N/A | $1.9M-61.4% | -$5.2M-208.2% | -$4.5M-8.1% | N/A | $4.9M-5.9% |
| Income Tax | $3.1M+107.3% | $12.2M-80.9% | N/A | -$14.1M-3670.1% | -$43.3M-707.8% | $64.0M+1100.8% | N/A | $395K-94.9% |
| Net Income | -$4.9M-102.5% | $331.0M+174.0% | -$412.2M-359.2% | -$50.6M-250.5% | $196.9M+2947.9% | -$447.5M-1339.0% | $159.0M+248.4% | $33.6M+182.1% |
| EPS (Basic) | -$0.05-102.5% | $3.15+168.5% | -$3.93-338.2% | -$0.50-242.9% | $2.01+2771.4% | -$4.60-1310.5% | $1.65+117.1% | $0.35+176.1% |
| EPS (Diluted) | -$0.05-102.6% | $2.88+162.6% | -$3.93-362.0% | -$0.50-247.1% | $1.89+2600.0% | -$4.60-1343.2% | $1.50 | $0.34+173.9% |
| Diluted Shares (Avg) | 105M-1.1% | 122M+25.2% | N/A | 100M-0.2% | 107M+7.5% | 97M-1.8% | N/A | 100M+13.0% |
Not reported in any period shown, so not listed: Cost of Revenue.
SRPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.2B-13.4% | $3.2B-8.3% | $3.3B-15.5% | $3.5B-3.0% | $3.7B+7.5% | $3.5B+7.5% | $4.0B+21.4% | $3.6B+15.8% |
| Current Assets | $2.2B-16.3% | $2.3B-5.0% | $2.5B-17.4% | $2.7B+1.4% | $2.7B-1.0% | $2.4B-1.3% | $3.1B+19.2% | $2.7B+9.6% |
| Cash & Equivalents | $571.1M+11.9% | $464.4M+92.8% | $801.3M-27.4% | $613.1M+209.9% | $510.6M+33.1% | $240.9M-43.6% | $1.1B+157.5% | $197.9M-63.5% |
| Short-Term Investments | $217.3M-24.9% | $188.7M-33.0% | $138.4M-45.0% | $237.9M-76.2% | $289.5M-73.1% | $281.9M-70.7% | $251.8M-79.8% | $1.0B-16.0% |
| Inventory | $904.3M-9.0% | $1.0B+6.3% | $914.7M+22.0% | $1.1B+90.3% | $994.0M+104.6% | $941.4M+152.0% | $750.0M+132.3% | $565.9M+131.9% |
| Accounts Receivable | $376.8M-28.5% | $394.8M-40.1% | $398.2M-33.8% | $395.7M-8.9% | $527.3M+46.5% | $659.4M+74.1% | $602.0M+50.4% | $434.5M+36.3% |
| Long-Term Investments | $145.4M+320.1% | $81.9M-24.9% | $1.0M-99.2% | $1.0M-99.4% | $34.6M | $109.1M+221.9% | $133.2M-68.9% | $181.8M |
| Total Liabilities | $1.7B-28.5% | $1.7B-27.9% | $2.2B-9.3% | $2.2B-8.6% | $2.3B-1.1% | $2.3B+2.6% | $2.4B+1.3% | $2.4B+1.4% |
| Current Liabilities | $502.9M-45.3% | $499.2M-17.6% | $1.1B+49.7% | $921.4M+31.7% | $919.9M+33.6% | $605.6M-0.5% | $731.7M+11.9% | $699.5M+55.2% |
| Non-Current Liabilities | $1.2B-17.4% | $1.2B-31.6% | $1.1B-34.6% | $1.3B-25.5% | $1.4B-15.4% | $1.7B+3.8% | $1.7B-2.7% | $1.7B-11.4% |
| Long-Term Debt | $847.6M | $838.2M | $829.0M-27.1% | $140.5M-88.6% | N/A | N/A | $1.1B-8.1% | $1.2B-0.7% |
| Total Equity | $1.5B+8.8% | $1.5B+26.5% | $1.1B-25.3% | $1.3B+8.1% | $1.4B+30.4% | $1.2B+23.8% | $1.5B+77.8% | $1.2B+59.8% |
| Retained Earnings | -$4.6B-2.0% | -$4.5B+2.4% | -$4.9B-15.8% | -$4.6B-6.2% | -$4.5B-1.3% | -$4.7B-5.6% | -$4.2B+5.3% | -$4.4B+2.7% |
Not reported in any period shown, so not listed: Goodwill.
SRPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $197.1M-24.6% | -$202.7M+65.3% | $131.2M+42.5% | -$14.6M+79.4% | $261.3M+1649.0% | -$583.4M-141.0% | $92.0M+268.4% | -$70.7M+38.4% |
| Depreciation & Amortization | $10.4M-4.0% | $10.6M+6.2% | $5.3M-49.8% | $18.4M+88.2% | $10.8M+24.3% | $10.0M+14.1% | $10.5M-8.1% | $9.8M-10.3% |
| Stock-Based Compensation | $24.5M-33.8% | $29.4M-29.0% | N/A | $14.9M-65.7% | $37.0M-26.7% | $41.4M+1.8% | N/A | $43.5M-9.6% |
| Capital Expenditures | $555K-98.3% | $2.1M-95.2% | $3.6M-90.6% | $22.9M-38.5% | $31.8M+9.0% | $43.7M+34.5% | $38.1M+100.0% | $37.3M+25.6% |
| Free Cash Flow | $196.5M-14.4% | -$204.8M+67.3% | $127.6M+136.5% | -$37.5M+65.2% | $229.5M+1713.6% | -$627.1M-128.4% | $54.0M+173.2% | -$108.0M+25.2% |
| Investing Cash Flow | -$93.4M-389.9% | -$134.4M+53.8% | $96.2M-87.4% | $232.4M+280.4% | $32.2M+132.7% | -$291.2M-233.1% | $764.1M+1287.3% | -$128.8M+38.8% |
| Financing Cash Flow | $0+100.0% | $241K-98.1% | -$39.2M-180.0% | -$117.8M-956.2% | -$23.8M-159.7% | $12.5M-43.7% | $49.0M+2421.4% | $13.8M-10.7% |
| Share Buybacks | N/A | N/A | $0 | $0 | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
SRPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | -6.6%-83.4pp | 54.9%-17.5pp | 59.0%-28.1pp | 63.6%-11.1pp | 76.8% | 72.4% |
| Operating Margin | 3.3%-15.6pp | 49.0%+89.4pp | N/A | -25.9%-30.6pp | 18.9%+19.1pp | -40.3%-48.8pp | N/A | 4.8%+11.0pp |
| Net Margin | -1.2%-33.4pp | 45.3%+105.4pp | -93.1%-117.2pp | -12.7%-19.9pp | 32.2%+30.4pp | -60.1%-68.8pp | 24.2%+12.7pp | 7.2%+19.5pp |
| Return on Equity | -0.3%-14.3pp | 22.0%+59.6pp | -36.1%-46.6pp | -3.8%-6.6pp | 14.0%+13.4pp | -37.6%-41.4pp | 10.4%+5.1pp | 2.8%+8.1pp |
| Return on Assets | -0.1%-5.5pp | 10.4%+23.3pp | -12.3%-16.3pp | -1.5%-2.4pp | 5.3%+5.2pp | -12.9%-14.0pp | 4.0%+2.6pp | 0.9%+2.3pp |
| Current Ratio | 4.42+1.5x | 4.63+0.6x | 2.32-1.9x | 2.95-0.9x | 2.89-1.0x | 4.020.0x | 4.20+0.3x | 3.84-1.6x |
| Debt-to-Equity | 0.55-1.1x | 0.56-1.4x | 0.730.0x | 0.11-0.9x | 1.65+0.5x | 1.95+0.7x | 0.74-0.7x | 1.01-0.6x |
| Asset Turnover | 0.130.0x | 0.230.0x | 0.130.0x | 0.110.0x | 0.17+0.1x | 0.21+0.1x | 0.170.0x | 0.130.0x |
| FCF Margin | 49.0%+11.4pp | -28.0%+56.2pp | 28.8%+20.6pp | -9.4%+13.7pp | 37.6%+41.5pp | -84.2%-17.8pp | 8.2%+26.8pp | -23.1%+20.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics,, Inc. SRPT | FY2025 | $2.2B | -$713.4M | -32.5% | $1.8B | 44/100 |
| Dyne Therapeutics, Inc. DYN | FY2025 | N/A | -$446 | N/A | $3.0B | — |
| Mesoblast Limited MESO | FY2025 | $17.2M | -$102.1M | N/A | $1.9B | 28/100 |
| Harmony Biosciences Holdings, Inc. HRMY | FY2025 | $868.5M | $158.7M | 18.3% | $2.3B | 88/100 |
| Immunocore Holdings plc IMCR | FY2025 | $400.0M | -$35.5M | -8.9% | $1.6B | 65/100 |
| ProKidney Corp. PROK | FY2025 | $893K | -$69.0M | N/A | $357.3M | — |
Where Sarepta Therapeutics,, Inc. Ranks
Frequently Asked Questions
What is Sarepta Therapeutics,, Inc.'s annual revenue?
Sarepta Therapeutics,, Inc. (SRPT) reported $2.2B in total revenue for fiscal year 2025. This represents a 15.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sarepta Therapeutics,, Inc.'s revenue growing?
Sarepta Therapeutics,, Inc. (SRPT) revenue grew by 15.6% year-over-year, from $1.9B to $2.2B in fiscal year 2025.
Is Sarepta Therapeutics,, Inc. profitable?
No, Sarepta Therapeutics,, Inc. (SRPT) reported a net income of -$713.4M in fiscal year 2025, with a net profit margin of -32.5%.
What is Sarepta Therapeutics,, Inc.'s EBITDA?
Sarepta Therapeutics,, Inc. (SRPT) had EBITDA of -$655.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sarepta Therapeutics,, Inc. have?
As of fiscal year 2025, Sarepta Therapeutics,, Inc. (SRPT) had $801.3M in cash and equivalents against $829.0M in long-term debt.
What is Sarepta Therapeutics,, Inc.'s gross margin?
Sarepta Therapeutics,, Inc. (SRPT) had a gross margin of 98.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sarepta Therapeutics,, Inc.'s operating margin?
Sarepta Therapeutics,, Inc. (SRPT) had an operating margin of -31.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sarepta Therapeutics,, Inc.'s net profit margin?
Sarepta Therapeutics,, Inc. (SRPT) had a net profit margin of -32.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sarepta Therapeutics,, Inc.'s return on equity (ROE)?
Sarepta Therapeutics,, Inc. (SRPT) has a return on equity of -62.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sarepta Therapeutics,, Inc.'s free cash flow?
Sarepta Therapeutics,, Inc. (SRPT) recorded an outflow of $307.5M in free cash flow during fiscal year 2025. This represents a 10.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sarepta Therapeutics,, Inc.'s operating cash flow?
Sarepta Therapeutics,, Inc. (SRPT) recorded an outflow of $205.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sarepta Therapeutics,, Inc.'s total assets?
Sarepta Therapeutics,, Inc. (SRPT) had $3.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sarepta Therapeutics,, Inc.'s capital expenditures?
Sarepta Therapeutics,, Inc. (SRPT) invested $102.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sarepta Therapeutics,, Inc. spend on research and development?
Sarepta Therapeutics,, Inc. (SRPT) invested $1.5B in research and development during fiscal year 2025.
What is Sarepta Therapeutics,, Inc.'s current ratio?
Sarepta Therapeutics,, Inc. (SRPT) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.
What is Sarepta Therapeutics,, Inc.'s debt-to-equity ratio?
Sarepta Therapeutics,, Inc. (SRPT) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sarepta Therapeutics,, Inc.'s return on assets (ROA)?
Sarepta Therapeutics,, Inc. (SRPT) had a return on assets of -21.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sarepta Therapeutics,, Inc.'s P/E ratio?
Sarepta Therapeutics,, Inc. (SRPT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sarepta Therapeutics,, Inc.'s price-to-sales ratio?
Sarepta Therapeutics,, Inc. (SRPT) trades at 0.9x sales, its market capitalization divided by revenue of $2.0B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Sarepta Therapeutics,, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sarepta Therapeutics,, Inc. (SRPT) held $940.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $205.5M over that year. Dividing the one by the other, the reported balance equals about 55 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Sarepta Therapeutics,, Inc.'s Altman Z-Score?
Sarepta Therapeutics,, Inc. (SRPT) has an Altman Z-Score of -1.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sarepta Therapeutics,, Inc.'s Piotroski F-Score?
Sarepta Therapeutics,, Inc. (SRPT) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sarepta Therapeutics,, Inc.'s earnings high quality?
Sarepta Therapeutics,, Inc. (SRPT) reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sarepta Therapeutics,, Inc. cover its interest payments?
Sarepta Therapeutics,, Inc. (SRPT) reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sarepta Therapeutics,, Inc.?
Sarepta Therapeutics,, Inc. (SRPT) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.